Patient Case Studies and Panel Discussion: Management of Acute Lymphoblastic Leukemia
The incorporation of tyrosine kinase inhibitors (TKIs), targeted agents, and CAR T-cell therapies into standard treatment regimens and the role of minimal/measurable residual disease (MRD) monitoring to identify patients who may benefit from further intensified therapies or alternative treatment strategies have significantly improved the outcomes of patients with Ph-positive acute lymphoblastic leukemia (ALL). However, these advances have increased the complexities of therapy selection. It is critically important for oncology care providers to be aware of the best ways to incorporate these advances into standard practice so that each patient can receive optimal care.
Target Audience
This educational program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, PAs, and other health care professionals who manage patients with hematologic malignancies.
Learning Objectives
Following this program, participants should be able to:
- Explain initial treatment strategies used in acute lymphoblastic leukemia (ALL) management.
- Review the role of minimal/measurable residual disease in the selection of consolidation therapy for patients with ALL.
- Discuss treatment options for patients with relapsed/refractory ALL.
Bijal Shah, MD
Moffitt Cancer Center
Mark R. Litzow, MD
Mayo Clinic Cancer Center
Aaron C. Logan, MD, PhD
UCSF Helen Diller Family Comprehensive Cancer Center
Nicholas J. Short, MD
The University of Texas MD Anderson Cancer Center
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Mark R. Litzow, MD
AbbVie, Inc.: Grant/Research Support
Actinium Pharmaceuticals, Inc.: Grant/Research Support
Amgen Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Grant/Research Support
BioSight Ltd.: Scientific Advisor
Jazz Pharmaceuticals Inc.: Scientific Advisor
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pluristem Therapeutics Inc.: Grant/Research Support
Syndax Pharmaceuticals Inc.: Grant/Research Support
Aaron C. Logan, MD, PhD
AbbVie, Inc.: Consulting Fee
Agios, Inc.: Consulting Fee
Amgen Inc.: Consulting Fee; Grant/Research Support
Astellas Pharma US, Inc.: Grant/Research Support
Autolus Therapeutics: Grant/Research Support
Bristol-Myers Squibb Company: Consulting Fee
Jazz Pharmaceuticals Inc.: Grant/Research Support
Kadmon Corporation: Grant/Research Support
Kite Pharma: Grant/Research Support
Pfizer Inc.: Consulting Fee
Pharmacyclics: Grant/Research Support
Bijal Shah, MD
Acrotech: Honoraria
Adaptive Biotechnologies: Honoraria
Amgen Inc.: Honoraria
AstraZeneca Pharmaceuticals LP: Honoraria
Autolus: Honoraria
BeiGene: Honoraria
Bristol-Myers Squibb Company/Celgene Corporation: Honoraria
Jazz Pharmaceuticals Inc: Grant/Research Support
Kite Pharma/Gilead Sciences, Inc.: Grant/Research Support; Honoraria
Novartis Pharmaceuticals Corporation: Honoraria
Pfizer Inc.: Honoraria
Pharmacyclics: Honoraria
Precision Biosciences, Inc: Honoraria
Servier: Grant/Research Support
Nicholas J. Short, MD
Amgen Inc.: Consulting Fee; Honoraria
Astellas Pharma US, Inc.: Grant/Research Support; Honoraria
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Consulting Fee
Stemline Therapeutics, Inc.: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support
Xencor: Grant/Research Support
Congress Planning Committee Disclosures
The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.
Brenda K. Shelton, DNP, RN, CCRN, AOCN, NPD-BC
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Gabriela S. Hobbs, MD
AbbVie, Inc.: Scientific Advisor
Agios, Inc.: Scientific Advisor
Bayer HealthCare: Grant/Research Support
Blueprint Medicines: Scientific Advisor
Bristol-Myers Squibb Company: Scientific Advisor
Celgene Corporation: Scientific Advisor
Incyte Corporation: Grant/Research Support; Scientific Advisor
Jazz Pharmaceuticals Inc.: Scientific Advisor
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor
Shaji K. Kumar, MD
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Amgen Inc.: Grant/Research Support; Scientific Advisor
BeiGene: Honoraria
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor
GlaxoSmithKline: Grant/Research Support; Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Karyopharm Therapeutics: Grant/Research Support; Scientific Advisor
Loxo Oncology, Inc.: Scientific Advisor
Regeneron Pharmaceuticals, Inc.: Grant/Research Support; Scientific Advisor
Roche Laboratories, Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support; Scientific Advisor
Bernard Marini, PharmD, BCOP
Servier Laboratories: Consulting Fee
Andrew D. Zelenetz, MD, PhD
AbbVie, Inc.: Consulting Fee
Adaptive Biotech: Consulting Fee
Amgen Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee; Grant/Research Support
BMS/Celgene/Juno: Consulting Fee; Scientific Advisor
Celgene Corporation: Consulting Fee
Genentech, Inc.: Consulting Fee; Grant/Research Support
Gilead Sciences, Inc./Kite Pharma: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc.: Consulting Fee; Grant/Research Support
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support
NCCN Staff Disclosures
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.25 contact hours.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-22-116-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until December 15, 2023. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 1.25 AAPA Category 1 CME credit
- 1.25 ACPE contact hours
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC contact hours
- 1.25 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing